Page 34 - IMR Annual Report 2022: Institute for Medical Research

IMR Annual
18
Report2022
INSTITUTE FOR MEDICAL RESEARCH

Principal
investigator/
NMRR
No. Research Title Number Co-principal
investigator
(Co-PI)

14 Molecular analysis of Factor VIII (F8) gene in NMRR ID-21- Nursaedah
Malaysian haemophilia A patients 02264-MSY Abdullah Aziz

15 Rapid detection of large beta-globin gene cluster NMRR-21- Dr. Yuslina
deletions causing an increased production in Hb F 1769-59749 Mat Yusoff
levels among Malaysian patients using a single tube
PCR method

16 Development of artificial intelligence model for NMRR ID-22- Nor Soleha
prognostication of multiple myeloma patients 00157-BWE Mohd Dali

17 Analysis of borderline HbA2 in Institute for Medical NMRR ID-22- Dr. Norafiza
Research (IMR) from 2017 to 2020 00185-DAV IIR Mohd Yasin

18 Validation of sequence variants of putative tumour NMRR ID-22- Hamidah
suppressor genes in nasopharyngeal carcinoma 00383-HGA Akmal
Hisham
19 The establishment of lymphoma patient-specific NMRR ID-22- Dr. Nurul Ain
Human-Induced Pluripotent Stem Cells (hiPSCs) and 00881-H6E Nasim Mohd
derived-cardiomyocytes (hiPSC-CMS) to investigate Yusof
doxorubicin induced-cardiotoxicity. A cardiotoxicity
disease modelling

20 Effects of intravenous administration of elixir NMRR ID-22- Dr. Susan
multicellular immune therapy (EMIT) in the xenograft 01559-HKD Hoe Ling
mice model of colorectal cancers (ISR) Ling

21 Analysing expressed Epstein–Barr virus variants and NMRR-18 Dr. Tan Lu
tumor microenvironment to understand the immune 264-40228 Ping
evasion in EBV associated cancers

22 Prevalence of human papillomavirus (HPV) - NMRR-21-629- Dr. Hans
associated head and neck squamous cell carcinoma 59503 Prakash
(HNSCC) In Malaysia Sathasivam

23 Multi-centre clinico-pathological study of Malaysian NMRR-20- Dr. Hans
patients with hepatocellular carcinoma 2550-57039 Prakash
Sathasivam

24 Multi-centre clinico-pathological study of Malaysian NMRR-20- Dr. Hans
patients with oral squamous cell carcinoma 1351-55551 Prakash
Sathasivam
Cancer Research Centre (CaRC) comparative, pivotal study evaluating the efficacy of 3513-42896 Prakash
Dr. Hans
The AIM-HN and SEQ-HN study: A 2 cohort, non-
25
NMRR-18-
Sathasivam
tipifarnib in patients with head and neck squamous
cell carcinoma (HNSCC) with HRAS mutations (AIM-
HN) and the impact of HRAS mutations on response
to first line systemic therapies for HNSCC (SEQ-HN)